Navigation Links
Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
Date:10/12/2007

ANALYST AVAILABLE TO COMMENT ON THE MARKET FORECAST FOR THE DRUG

WALTHAM, Mass., Oct. 12 /PRNewswire/ -- Dr. Sylvia Eash, Ph.D., analyst at Decision Resources, is available to discuss the impact of the Food and Drug Administration's (FDA) possible approval of Merck's Isentress, the first integrase inhibitor drug which blocks the ability of the HIV virus to replicate and infect new cells.

Integrase inhibitors are a novel class of HIV drugs aimed at a previously unexploited viral target. They are a key new class that will expand therapeutic options for HIV patients and stand out as one of the most promising emerging classes in development for HIV. The reported efficacy and safety data from clinical trials of Isentress indicate that the product is highly efficacious, safe, well tolerated in both treatment-naive and treatment-experienced HIV patients. The clinical data on Isentress presented to date suggests that there is significant opportunity for follow-on agents in this new class of HIV drugs.

Isentress is expected to launch during the fourth quarter of 2007, according to Merck.

Dr. Eash can provide:

-- Insight on the class of integrase inhibitors and particularly Isentress

and its potential effect on other drugs in the HIV market.

-- Key factors that will have an impact on Isentress's uptake and use. How

will Isentress be positioned in the lines of HIV treatment?

-- The main drivers and barriers for its use. What is the forecast for

Isentress? Which drugs will be its main competition?

-- Key thought leaders' perceptions about Isentress.

-- Isentress's impact on the HIV market and on the overall HIV therapeutic

approach.

Sylvia Eash, Ph.D., is an analyst with Decision Resources Infectious Disease group, where she evaluates emerging therapies and develops market forecasts. She has a doctoral degree in pathobiology from Brown University. Dr. Eash is the author of several peer-reviewed primary literature and review articles, and she is a member of the American Society for Microbiology and the International Society of Neurovirology.

To talk with Dr. Eash, please contact Erica Ames at 781-296-2583 or eames@dresources.com.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Erica Ames

781-296-2583

eames@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. A Vaccine for the impending pandemic Avian Influenza
2. India warned of Impending AIDS Disaster
3. 3-D Ultrasound Identifies Women at Risk for Impending Preterm Birth
4. Now, Cellphones That Alert Against Impending Lightning Strikes
5. WHO Gives Its Approval For Bird Flu Test Kit
6. Ranbaxy gets US FDA approval for Lisinopril
7. Approval for DNA test to detect cystic fibrosis
8. Aurobindo gets U.S. FDA approval for Cephalexin
9. Cadila gets US FDA approval for Promethazine tablets
10. Vaccine For Cervical Cancer Awaits Approval
11. Anti-obesity drugs for FDA approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... NY & Salt Lake City, UT (PRWEB) , ... February 05, ... ... Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author ... the New Really Cool Humans Amateur TV Network. , Each week, on his weekly ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Wegener Polyangiitis ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline Review, ... Polyangiitis,s therapeutic pipeline. This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... SILVER SPRING, Md. , Feb. 4, 2016 ... Robert Califf , the FDA,s Deputy Commissioner for Medical Products ... far-reaching action plan to reassess the agency,s approach to opioid ... the epidemic, while still providing patients in pain access to ... The FDA will: , Re-examine the risk-benefit ...
Breaking Medicine Technology: